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The p53 tumour suppressor gene codes for protein that regulates
the expression of various genes and affects many cellular functions
including: DNA repair, cell cycle checkpoints and apoptosis
(reviewed in Harris, 1996; Ko and Prives, 1996; Levine, 1997).
The p53 protein activates transcription of the WAF1/CIP1,
encoding a 21 kDa protein (El-Deiry et al, 1993) associating with
the cyclin D1–cyclin- dependent kinase (cdk)4 complex and
inhibiting its kinase activity. This in turn prevents the cell from
entering the S phase of the cell cycle (Harper et al, 1993; Xiong et
al, 1993). Mutations in p53 lead to the loss of tumour suppressor
function and also can result in a gain-of-function phenotype of
mutant protein (Gualberto et al, 1998 and refs therein). Missense
mutations lead to the abnormal accumulation of p53 protein which
can be visualized by immunohistochemical methods (Iggo et al,
1990). Abnormal accumulation of p53 and p53 mutations are
frequent in precancerous lesions (dysplasia) of lung epithelium
(Sozzi et al, 1992; Vahakangas et al, 1992; Bennett et al, 1993).
p53 mutation spectra may give clues to the aetiology of cancer
(Hollstein et al, 1991; Harris 1993; Greenblatt et al, 1994; Hussain
and Harris, 1998). Thirty per cent of p53 point mutations in lung
cancers from smokers are G:CÕ T:A transversions, and most of the
G residues are on the DNA non-transcribed strand (Greenblatt et al,
1994). The non-transcribed strand of the p53 is repaired at a slower
rate than the transcribed strand (Evans et al, 1993). G:CÕT:A trans-
versions are significantly less frequent in never smokers
(Takeshima et al, 1993; Greenblatt et al, 1994; Hainaut et al, 1998:
the database for p53 mutations). These transversions may be attrib-
uted to either bulky chemical carcinogens (e.g. benzo[a]pyrene) or,
perhaps, oxyradical exposure resulting, for example, from tobacco
smoking (Ruggeri et al, 1993; Denissenko et al, 1998).
Tobacco smoking is a predominant cause of human lung cancer
(reviewed in IARC Monograph, 1986). The contribution of air
pollution to the aetiology of lung cancer is less clear, which may
reflect the limited sensitivity of epidemiological studies. The role
of occupational and environmental exposure to polluted air is
supported by some studies (Miller, 1992; Petersen, 1994; Speizer
and Samet, 1994).
Silesia is a highly industrialized and densely populated region in
southern Poland with considerable air pollution (Chorazy et al,
1994). Previous studies have shown that non-occupationally
exposed Silesian residents have more chromosomal aberrations,
sister chromatid exchanges and PAH-DNA adducts than rural
controls (Motykiewicz et al, 1992; Perera et al, 1992; Grzybowska
et al, 1993; Motykiewicz et al, 1995).
Gene–environment interactions may influence the risk of
cancer. Aryl hydrocarbon hydroxylase (AHH) and debrisoquine
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have been studied extensively in lung cancer patients with varying
results. Initial CYP2D6 phenotyping studies suggested overrepre-
sentation of the dominant EM (extensive metabolizer) phenotype
in lung cancer patients when compared to patients with chronic
obstructive pulmonary disease (Ayesh et al, 1984; Caporaso et al,
1989). Subsequent genotyping reports have not confirmed these
findings (Sugimura et al, 1990; Tefre et al, 1994; Stucker et al,
1995). Caporaso et al (1995) discussed the possible explanation of
these apparent paradoxical findings. For CYP1A1, the polymorphic
minor allele codes for valine in exon 7 (codon 462) instead of
isoleucine. A significant preponderance of the susceptible Val/Val
genotype among individuals with lung cancer has been reported in
a Japanese population (Hayashi et al, 1992). The glutathione-S-
transferase (GSTM1) gene encodes glutathione S-transferase class
m that catalyses conjugation reactions of glutathione with electro-
philes (e.g. activated PAHs). Some reports have observed that lack
of GSTM1 activity due to the homozygous deletion confers
increased lung cancer risk (Hirvonen et al, 1993; Alexandrie et al,
1994; Kihara et al, 1994; reviewed by Rebbeck, 1997). This
increased lung cancer risk is compounded for carriers of CYP1A1
susceptibility genotypes (Hayashi et al, 1992; Nakachi et al, 1993).
The specific aim of our investigation was to determine molec-
ular and immunohistochemical changes (p53 gene mutations, p53
protein accumulation and WAF1 protein expression) in a case
series of non-small-cell lung cancer (NSCLC) samples from a
heavily polluted area of Poland. We investigated the hypothesis
that the p53 mutational spectrum in the Silesian residents reflects
the mutagenic activity of air pollution. Our analyses also examined
possible relationship between the mutational spectrum of p53 and
selected functional genetic polymorphisms involved in carcinogen
metabolism.
MATERIALS AND METHODS
Sample collection
The cases of NSCLC were resected at the Department of Thoracic
Surgery, Silesian Medical Academy between 1991 and 1995. The
patients were interviewed at the hospital by either a physician or a
trained nurse. Data on demographics, medical history, family
history of cancer, occupational exposure and smoking habits were
collected by questionnaire. Tumour and non-tumour samples were
either frozen on dry ice (all non-tumour lung and 45 tumour
samples) or fixed (see below) and paraffin-embedded (119 tumour
samples). Forty-five tumour samples were not available for
paraffin embedding. DNA from fresh tissues was extracted, after
crushing in liquid nitrogen, using standard procedures (Sambrook
et al, 1989). Cancer cells were not microdissected from tumour
samples. DNA from dewaxed paraffin sections of tumour tissues
was extracted by sodium dodecyl sulphate (SDS)–proteinase K
treatment (0.5 mg ml–1 in 1% SDS) at 55°C for 18–24 h followed
by phenol–chloroform extraction and ethanol precipitation with
glycogen as a carrier.
Immunohistochemistry
Immediately after the surgical removal, the tissues were fixed for
24 h in either ice-cold 10% formalin in phosphate-buffered saline
(PBS), or in methacarn (methanol:chloroform:acetic acid 6:3:1)
and embedded in paraffin. A portion of each specimen also was
fixed by 4% paraformaldehyde in PBS. Immunohistochemical
staining was performed on dewaxed 7-mm sections. Formalin-
fixed tissues sections were heated 2 ´ 5 min in a microwave oven
in 0.01 M citric buffer, pH 6.0. The p53 protein was detected using
either the polyclonal antibody CM1 (Signet Laboratories) or one
of the following monoclonal antibodies: Ab 1801 (Ab 2,
Oncogene Sciences, Gaithersburg, MD, USA), DO-1 (Ab 6,
Oncogene Sciences) recognizing epitopes on the amino-terminus
of the p53 protein chain (amino acids 40–65 and 37–45 respec-
tively), HR231 (a gift of Dr T Soussi) that reacts with amino acids
351–393 on the carboxy-terminus of the p53 protein (Legros et al,
1993). All used antibodies recognize both the wild-type and
mutant p53. The four anti-p53 antibodies yielded a very similar
staining pattern, but the intensity of staining varied slightly. There
was no instance of a positive result with one antibody contradicted
by lack of staining with another.
For detection of the p21WAF1/CIP1 protein, sections of tissue fixed
in formalin and exposed to microwave antigen retrieval were used.
The sections were incubated overnight at 4°C with the primary
antibody (mouse monoclonal antibody Ab-1 from Oncogene
Sciences). Indirect immunoperoxidase staining with avidin–biotin
or streptavidin peroxidase complexes and 3,3¢-diaminobenzidine
as a substrate was applied for visualization of the antigens. The
sections were counterstained with Mayer’s haematoxylin.
p53 and p21Waf1 immunohistochemical analysis of the intensity
of positive staining was scored as follows: + 2–10% of cells
distinctly positive or more cells weakly stained, ++ 10–50%
distinctly positive or more cells weakly stained, +++ more than
50% of cells strongly stained.
Mutational analysis of the p53 gene
Exons 5 to 8 of p53 were amplified by polymerase chain reaction
(PCR) with intronic primers (Lehman et al, 1991) and sequenced
with Sequenase Version 2.0 DNA sequencing kit (USB-Amersham,
Cleveland, OH, USA). When PCR amplification was strong, the
PCR product was sequenced with Sequenase PCR product
sequencing kit (USB-Amersham). A DNA fragment with mutation
was reamplified and resequenced to confirm that the mutation was
not introduced by an error of the thermostable polymerase used for
PCR. Germline mutations were excluded by PCR amplification and
sequencing of relevant exons from non-tumour lung DNA.
Genotyping of GSTM1, CYP2D6 and CYP1A1
The CYP1A1 exon 7 and GSTM1 polymorphisms were determined
as described previously (Shields et al, 1993). In a multiplex PCR
reaction, a CYP1A1 fragment served as an internal control for the
detection of the GSTM1 gene deletion. The CYP1A1 fragment was
analysed by NcoI restriction enzyme digestion. The CYP2D6-A
allelic variant was detected using allele-specific double-step PCR
according to Heim and Meyer (1990). The CYP2D6-B allele was
identified using PCR and BstNI digestion as previously described
by Kato et al (1995).
Statistical analyses
Descriptive statistics and standard measures of association (e.g.
cross-tabulations using c2 test for association) were used for data
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performed using the Statistica Version 5.0 program for PCs
(StatSoft, Inc., Tulsa, OK, USA) or Statistical Analysis System
(Cary, NC, USA). Mutational spectra of the p53 were compared
using a computer program developed by Cariello et al (1994). It
can be obtained at http://sunsite.unc.edu/dnam/mainpage.html. We
refer to it as Monte Carlo analysis. The differences were consid-
ered statistically significant if the P-value was 0.05 or less in two-
tailed tests.
RESULTS
Exons 5–8 of p53 were sequenced directly after PCR amplification
from genomic DNA of 164 patients without pre-selection of
samples. Ninety-two somatic mutations were found in 90 patients
(55%). In two patients, we found two p53 mutations. In sample no.
288, which stained positively for the p53 protein, one base pair dele-
tion in exon 5 (codon 159) and a mis-sense mutation in exon 8
(codon 275) were found. In sample no. 217, which stained positively
p53 mutations and air pollution 1447
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Table 1 Frequency of p53 mutations in non-small-cell lung cancers from Silesia, Poland
All mutations SQ AD LG Smokers Never smokers Coal-exposed Coal non-exposed
G:C®T:A 31 20 55 50 29 39 37 24
G:C®A:T 29 33 30 0 31 20 20 34
G:C®C:G 9 12 0 10 9.5 7 8 12
A:T®T:A 4.5 5 0 10 4 7 2.5 5
A:T®C:G 5.5 5 5 10 5 7 5 10
A:T®G:C 9 10 10 0 9.5 7 12.5 5
del/ins 12 15 0 20 12 13 15 10
Number of mutations n = 90 n = 59 n = 20 n = 10 n = 75 n = 15 n = 40 n = 41
Except for the bottom row the numbers are per cents. Two mutations are not included because they represent either tandem or composite mutation. One
mutation is not included in the histological column because the tumour was of mixed type. Coal-exposed and non-exposed patients were males. Using
mutational spectra comparison software, the only significant differences were found between spectra in SQ vs AD (P = 0.042; Monte Carlo analysis) and
between AD vs LG (P = 0.029; Monte Carlo analysis). Moreover, the difference of G:CÕT:A frequencies in SQ vs AD was also significant (P = 0.008; c2).
Table 2 Tumour types, p53 immunohistochemical staining and p53 mutations in coal-exposed and non-exposed NSCLC cases (males only)
Coal-exposed Non-exposed Significance
SQ + LG 59 (84%) 46 (68%)
AD 11 (16%) 22 (32%) P = 0.04 c2
p53 IHC-positive 24 (50%) 40 (77%)
p53 IHC-negative 24 (50%) 12 (23%) P = 0.01 c2
p53 mutations 39 (56%)a 41 (60%)
No p53 mutation detected 31 (44%) 27 (40%) P = 0.71 c2
p53 missense mutation 26 (67%) 30 (75%)
Other p53 mutationsb 13 (33%) 10 (25%)c P = 0.57 c2
Non-codon 298 mutation 35 (90%) 41 (100%)
Codon 298: GAGÕTAG 4 (10%) 0 P = 0.05 Fisher’s
aOne exposed patient had two mutations; bNon-sense mutations, deletions and frameshifts; cOne silent mutation was not included. SQ,
squamous cell carcinoma; AD, adenocarcinoma; IHC, immunohistochemistry.
Table 3 Gender, smoking status and GSTM1, CYP1A1 and CYP2D6 genotypes
GSTM1– CYP1A1 CYP2D6
Null Positive Ile/Ile Ile/Val BB or AB WT + A or B WT/WT
Females 13 8 17 4 2 8 11
(62%) (38%) (81%) (19%) (9.5%) (38%) (52.5%)
Males 70 65 115 20 7 51 77
(52%) (48%) 1* (85%) (15%) 2* (5%) (38%) (57%) 3*
Smokers 69 64 114 19 8 50 75
(52%) (48%) (86%) (14%) (6%) (38%) (56%)
Never 14 9 18 5 1 9 13
smokers (61%) (39%) 4* (78%) (22%) 5* (4%) (39%) (57%) 6*
1* P = 0.53 c2; 2*P = 0.86 Yates corrected c2; 3* P = 0.77 Yates corrected c2 (BB or AB vs others); 4* P = 0.57 c2; 5* P = 0.54 c2; 6* P = 0.87 Yates corrected c2
(BB or AB vs others).for p53 protein, a non-sense mutation in exon 8 (codon 298) and a
missense mutation in exon 7 (codon 246) were detected.
The frequency of p53 mutations in large-cell carcinomas (LG),
squamous cell carcinomas (SQ) and adenocarcinomas (AD) was:
83% (10/12), 56% (60/107) and 43% (19/44) respectively (one
tumour was diagnosed as of mixed histology).
A statistically significant difference of p53 mutation frequency
was found between AD and LG (P = 0.02, Fisher’s exact test), the
other differences were not statistically significant. No statistically
significant association was detected between the presence of p53
gene mutations and gender, T stage (characterizing primary
tumour size), N stage (characterizing presence of cancer invasion
to local lymph nodes) or general stage (I, II or III) of lung cancer
(combining the data on: primary tumour size, spread of cancer
tissue to local lymph nodes, presence on distant metastases).
Five mutational hotspots were detected (with at least four muta-
tions in each) at codons: 155 (n = 4), 158 (n = 4), 248 (n = 7), 273
(n = 5) and 298 (n = 5). Mutational spectra of the p53 gene in the
selected groups of patients and the spectrum of all mutations are
shown in Table 1. It was found that the spectra in smokers and
never smokers do not differ significantly, although G:CÕT:A
transversions were more frequent in never smokers (39%)
compared with smokers (29%; Table 1). We did not find a
dose–response relation between the number of smoked cigarettes
(pack-years) and either the frequency of mutations or the
frequency of G:CÕT:A transversions (data not shown).
In our series of patients, 70 males were occupationally exposed
to either coal dust or coal processing substances (54 coal miners,
but also foundry workers and others). The percentage of histolog-
ical types in coal-exposed versus non-exposed individuals (males
only) is shown in Table 2. The observed differences are statistically
significant (P = 0.04, c2 test). Four non-sense mutations in codon
298 (GAGÕTAG; GluÕSTOP) were found among 39 coal-exposed
males with mutated p53, whereas no non-exposed male patient out
of 41 with mutated p53 showed this mutation (P = 0.05 by Fisher’s
exact test). The overall spectra in coal-exposed and in non-exposed
male patients did not differ (Table 1). We observed that tumours of
non-coal-exposed patients tended to stain positively for p53 (40/52,
77%) when compared to coal-exposed patients (24/48, 50%); (P =
0.01, c2, Table 2). No significant association between the exposure
to coal and the presence of p53 gene mutations (Table 2) was
detected, although, consistent with immunohistochemical data,
males exposed to coal had more mutations (frameshifts, splice site
mutations, non-sense mutations) coding for truncated, rapidly
degraded p53 molecules, than non-exposed males (33% and 25%
respectively; P = 0.57 by c2, Table 2).
G:CÕT:A transversions were more frequent in males (26/82,
32%) than in females (2/8, 25%), but the difference was not statis-
tically significant. The frequency of all p53 mutations was lower in
females (8/21, 38%) compared to males (82/143, 57%; P = 0.16 by
c2). The gender difference in the frequency of p53 mutations
(although not significant) is likely related to lower frequencies of
p53 mutations in AD which have, in our sample set, a higher
prevalence in females (10/21; 48%) compared to males (34/143;
24%; P = 0.04 by c2).
In our case series AD were more frequent in never smokers (9/23;
39%) than in smokers (35/140; 25%; P = 0.25 by c2). But in never
smokers with a mutated p53 gene (15 individuals) AD constitute
only 26% of cases (four in 15) and only one of the AD had G:CÕT:A
transversion. Thus, most of G:CÕT:A transversions frequently
observed in never smokers (39%) are found in SQ and LG.
G:CÕT:A transversions showed a strong strand bias: 96% of G
nucleotides were located on the DNA coding (non-transcribed)
strand and only 4% on the non-coding (transcribed) strand. The
bias was stronger in smokers (100%) than in never smokers (86%).
In contrast, the DNA strand bias was not observed for G:CÕA:T
transitions (54% of G nucleotides on coding strand, 46% on non-
coding strand).
The  GSTM1,  CYP1A1 (exon 7 polymorphism) and CYP2D6
(alleles A and  B) genotypes were determined in 156 NSCLC
patients (Table 3). Normal tissue from eight cases was not avail-
able. Eighty-three patients were found to be GSTM1-null (53%)
and 24 patients were heterozygous for exon 7 polymorphism of
CYP1A1 gene (15%). We did not find any patient who was
homozygous for the minor Val allele of CYP1A1 (allele frequency
0.08). For CYP2D6, we found 88 (56%) patients who had neither
A nor B alleles (predicted phenotype EM), 59 (38%) patients who
were heterozygous for one of the mutant alleles A or B (predicted
phenotype IM – intermediate metabolizers), and nine (6%)
patients who carried either two B alleles or A and  B alleles t
(predicted phenotype PM – poor metabolizers).
No statistically significant gender differences were found of
genotype frequencies (Table 3) although the GSTM1-null geno-
type was more frequent in females. The genotype frequencies in
smokers and in never smokers are shown in Table 3. Analysis of
genotype frequencies by smoking history showed that frequencies
of ‘at risk’ genotypes of GSTM1 (null) and CYP1A1 (Ile/Val) were
higher in never smokers than in smokers, but the differences were
not statistically significant (Table 3). The relation between geno-
types and p53 mutations and p53 protein overexpression are
shown in Table 4. No statistically significant associations between
the variables were observed.
We did not observe any statistically significant association
between combined GSTM1 and CYP1A1 polymorphisms (GSTM1-
positive/CYP1A1 Ile/Val, GSTM1-positive/CYP1A1 Ile/Ile, GSTM1-
null/CYP1A1 Ile/Val, GSTM1-null/CYP1A1 Ile/Ile) and the muta-
1448 M Rusin et al
British Journal of Cancer (1999) 80(9), 1445–1452 © 1999 Cancer Research Campaign 
7% 13%
7%
7%
7%
20%
39%
Silesian never smokers
(n = 15)
p53 database never smokers
(n = 34)
29%
3% 6%
3%
47% 12%
Silesian smokers
(n = 75)
9% 12%
5%
9%
4%
32%
29%
p53 database smokers
(n = 256)
10% 11%
3%
11%
4%
27%
34%
Legend
A:T to T:A A:T to G:C
G:C to C:G G:C to T:A
A:T to C:G Del + ins.
G:C to A:T
Figure 1 Mutation spectra of p53 in NSCLC from Silesian patients and from
the database of p53 mutations (Hainaut et al, 1998). Note that the spectra of
Silesian smokers, never smokers and smokers from the database are almost
identical (Silesia smokers vs database smokers, P = 0.89; Monte Carlo
analysis), whereas the spectrum of p53 mutations in never smokers from the
database is significantly different from Silesian never smokers (P = 0.03;
Monte Carlo analysis)tions in p53 in a group of 133 smokers for whom the genotyping data
were available. We also compared the mutation spectra of the p53
gene among GSTM1-positive and GSTM1-null smokers. The p53
mutational spectra in neither group showed statistically significant
differences although the deletions/insertions were more frequent in
GSTM1-positive individuals (7/40; 18%) than in GSTM1-null ones
(2/34; 6%; P = 0.17 Fisher’s exact test). In never smokers we found
that almost all (12/13; 92%) GSTM1-null individuals stained positive
for the p53 protein whereas only 38% (3/8) GSTM1-positive individ-
uals stained positive for the p53 protein (P = 0.014 by Fisher’s exact
test). A similar relation was observed in never smokers for the
mutations of the p53 gene: 79% (11/14) GSTM-null individuals had a
mutated p53 gene, whereas only 44% (4/9) GSTM1-positive individ-
uals had mutations in p53; however, this difference was not statisti-
cally significant (P = 0.18; Fisher’s exact test).
The accumulation of p53 protein determined by immunohisto-
chemical methods was examined in 119 cases. Immunostaining for
p53 was most prominent in the formalin-fixed tissue after
microwave treatment, distinct in methacarn-fixed tissue and often
either a low or false-negative in formalin-fixed material without
antigen retrieval. The p53 immunostaining was found almost
exclusively in nuclei of cancer cells. In some cases, single positive
cell nuclei were visible in bronchial epithelium or among cells of
lymph nodules. Distinct cytoplasmic localization was found in
positive cases in some mitotic cancer cells. Accumulation of p53
was detected in 75 (63%) out of a total of 119 tumours examined
for p53 protein expression.
All 119 cases examined for p53 protein staining were also
analysed by the sequencing of exons 5–8 of p53. There were no
missense mutations among p53 immunohistochemically negative
cases. Thirty of the 119 cases (25%) showed neither mutation of
the p53 gene nor accumulation of the p53 protein, whereas 89
cases (75%) showed either mutations of the p53 gene (14/89) or an
accumulation of p53 protein (21/89) or both (54/89). Statistical
analyses (Student’s t-test) showed that the mutation of the p53
gene is significantly associated with strong immunohistochemical
staining of the p53 protein (P = 0.001). We found no association
between the stage of the disease and the immunohistochemical
staining of the p53 protein.
The immunohistochemical analyses of the p21WAF1/CIP1 antigen
were studied in 119 NSCLC cases immunostained also for p53
protein. Of three fixatives used, both PAF and formalin yielded posi-
tive immunostaining of p21WAF1/CIP1 after antigen retrieval, while
methacarn proved to be unsuitable for the purpose. The p21WAF1/CIP1
staining was found to be localized in tumour cell nuclei. In some
cases, single nuclei of the bronchial epithelium or cells within lymph
nodules were also positive. A positive reaction for p21WAF1/CIP1 was
present in 82 cases (69%). The majority of p21WAF1/CIP1-positive cases
also were reactive with anti-p53 antibodies (56/82; 68%). Samples
showing a strong immunohistochemical reaction for p21 protein
(++) more frequently showed strong (++ or +++) (19/25; 76%)
rather than a weak or negative (6/25; 24%) staining for p53 protein.
Among 37 cases negative for p21WAF1/CIP1 staining, only 19 (51%)
showed a positive immunostaining for p53.
In some tumour foci of well-differentiated squamous cell carci-
nomas, the immunoreaction for p53 was observed in basal cell
layers, whereas p21WAF1/CIP1-positive cells were localized in layers
of differentiating cells, sometimes displaying the features of kera-
tinization. In other cases, the positive cells were randomly distrib-
uted in the cancer tissue. Co-localization of both p53 and p21WAF1
antigens in the same cell nuclei was also observed.
No association was found between p21WAF1/CIP1 IHC staining and
any of the following: gender, smoking status, histology, occupa-
tional exposure, the stage of the disease or the mutation of the p53
gene (data not shown). When immunohistochemical staining for
p21 and p53 was combined, no association between combined
staining (both negative, either positive, both positive) and gender,
histology or disease stage was found (data not shown).
DISCUSSION
The DNA sequence was determined for exons 5–8 of p53 of 164
primary NSCLC from Silesia, a heavily polluted region of Poland.
Mutations of p53 were found in tumours of 90 patients (55%). The
most frequent mutation type was G:CÕT:A transversions (31%),
which is in agreement with the data of other authors (Figure 1)
(Greenblatt et al, 1994; Hainaut et al, 1998: the database of p53
p53 mutations and air pollution 1449
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Table 4 GSTM1, CYP1A1 and CYP2D6 genotypes and p53 gene and protein
Genotype p53 seq p53 IHC p53 seq + IHC
GSTM1 WT MUT Negative Positive Not altered Altered
Null 39 44 19 41 13 70
(47%) (53%) (32%) (68%) (16%) (84%)
Positive 30 43 22 30 14 59
(41%) (59%) 1* (42%) (58%) 2* (19%) (81%) 3*
CYP1A1 p53 seq p53 IHC p53 seq + IHC
Ile/Ile 57 75 36 60 25 107
(43%) (57%) (38%) (62%) (19%) (81%)
Ile/Val 12 12 5 11 2 22
(50%) (50%) 4* (31%) (69%) 5* (8%) (92%) 6*
CYP2D6 p53 seq p53 IHC p53 seq + IHC
BB or AB 36 3 3 2 7
(33%) (67%) (50%) (50%) (22%) (78%)
WT/B or 66 81 38 68 25 122
WT/A or (45%) (55%) 7* (36%) (64%) 8* (17%) (83%) 9*
WT/WT
1* P = 0.56 c2; 2* P = 0.33 c2; 3* P = 0.71 c2; 4* P = 0.69 c2; 5* P = 0.84 c2; 6* P = 0.33 Yates corrected c2; 7* P = 0.74 Yates corrected c2; 8* P = 0.79 Yates
corrected c2; 9* P = 0.96 Yates corrected c2.mutations). Surprisingly, G:CÕT:A transversions were more
frequent, although not significantly, in Silesian never smokers than
in smokers (39% and 29% respectively, Table 1 and Figure 1). This
was in contrast with p53 mutational spectrum in never smokers
from other populations (Figure 1) which showed a predominance
of G:CÕA:T transitions (47%). Unfortunately, the lung cancer
incidence in Silesian never smokers is not known. Our data are a
tentative indication that occupational and environmental exposure
to polluted air contributes to the molecular pathogenesis of lung
cancer in never smokers. To test this hypothesis further, the p53
mutation data from never smokers living in less polluted areas are
needed.
In contrast to other reports (Takeshima et al, 1993; Wang et al,
1995; Kondo et al, 1996), we did not find a dose–response relation
between the number of smoked cigarettes (pack-years) and
either the frequency of all p53 mutations or the frequency of p53
G:CÕT:A transversions, which may be explained by the
confounding effect of environmental air pollutants. Also it is
of interest that 100% of the G:CÕT:A transversions in smokers
(22 mutations) showed DNA strand bias for the DNA coding
strand, which was higher than in other populations studied
(reviewed by Greenblatt et al, 1994). The similarity of the muta-
tional spectrum in smokers from our case series and spectra
reported by others from Caucasian and Oriental populations may
result from a considerable influence that the carcinogens in
tobacco smoke have on the mutational processes in target lung
cells apart from either the differences in local environment or the
differences in genetic background of populations. The spectrum of
mutations in p53 in never smokers may reflect also differences in
either local environment or in the genetic makeup of populations.
Future molecular epidemiological studies on p53 mutations from
never smoking lung cancer patients of various ethnic, environ-
mental and occupational backgrounds will clarify these issues.
We detected five p53 mutational hotspots. The most intriguing
one is codon 298. Four of its G to T transversions are found in
coal-exposed males (all were coal miners) and only one in a non-
miner. Two of the miners were never smokers. This mutation is
very rare in lung cancers from other geographical regions of the
world. The frequency difference is significant for all p53 muta-
tions in NSCLC in the database (5/92 vs 6/495; P = 0.03; Yates
corrected c2; Hainaut et al, 1998). These data generate the hypoth-
esis that the codon 298 GAG to TAG mutation in coal miners is
induced by a carcinogen to which the miners are exposed.
According to our knowledge this is the first report of the spectrum
of p53 mutations in lung cancers from coal miners. We also noted
that males exposed to coal dust and coal-processing substances
differed significantly from non-exposed males in frequency of
histological types. Adenocarcinomas were much less frequent in
exposed than in non-exposed males and non-adenocarcinomas
were associated with coal exposure. It is of further interest that
tumours in males occupationally non-exposed to coal stained more
frequently for the p53 protein than tumours of occupationally-
exposed males (P = 0.01 by c2). This, in part, could be explained
by a higher frequency of loss-of-function mutations in coal-
exposed males (33%) compared with non-exposed ones (25%;
Table 2). The apparent discrepancy between the p53 immunohisto-
chemistry status and p53 sequencing data in Table 2, can result
from the fact that small deletions, insertions and non-sense muta-
tions generally lead to no detectable p53 protein and, therefore,
negative p53 immunohistochemistry staining. Conversely, positive
p53 immunohistochemistry staining can result from other mecha-
nisms than p53 mutations that are not understood at present.
The epidemiological data indicate that lung cancer mortality is
not elevated in Polish coal miners (Starzynski et al, 1996). This is
consistent with the results of studies performed on coal miners
from other countries, e.g. UK, USA, The Netherlands (Miller and
Jacobsen, 1985; Meijers et al, 1991; Kuempel et al, 1995). We do
not suggest that there is a substantial lung cancer risk in coal
miners. Most of the coal miners from our patient series were
smokers. It is conceivable that some carcinogens in coal mines
with concurrent tobacco smoking do not substantially increase
lung cancer risk but induce a different ‘pathway’ of cancer forma-
tion, hence, for example, an elevated frequency of non-adenocarci-
nomas and p53 immunohistochemistry-negative tumours in coal
exposed patients (Table 2). The similar analyses performed on coal
miners from other countries would be of great value.
Significant differences in the p53 mutational spectra between
adenocarcinomas and squamous cell carcinomas and between
adenocarcinomas and large cell carcinomas were detected in our
case series. The most striking difference in mutational spectra
between adenocarcinomas and squamous cell carcinomas was the
frequency of G:CÕT:A transversions, which are much more
frequent in adenocarcinomas (55%) than in squamous cell carci-
nomas (20%; P = 0.008; c2; Table 1). When only G:CÕT:A trans-
versions showing DNA strand bias (G base located on DNA
coding strand) were considered, the difference was even more
obvious (55% vs 19%).
The higher susceptibility to lung cancer was associated with the
exon 7 polymorphism of CYP1A1 gene in Japanese population.
The frequency of Val allele in Japanese lung cancer patients is 0.26
(Nakachi et al, 1993). It was also shown that the p53 gene is more
frequently mutated in patients with the CYP1A1 Val/Val genotype
(Kawajirii et al, 1996; Przygodzki et al, 1998). We have not
detected the similar relationship in our case series (not shown).
However, only 15% of the patients were heterozygous for the Val
allele so that our study does not have sufficient statistical power to
adequately test the hypothesis proposed by Kawajiri et al (1996).
GSTM1-null heavy smokers have a higher risk of transversion
mutations in the p53 gene (Ryberg et al, 1994), although it was not
observed by other investigators (Kawajirii et al, 1996). In the
Silesian cases, the spectrum of p53 mutations is similar among
smokers who are GSTM1 wild-type and null. Moreover, in contrast
with the report of Ryberg et al (1994) GSTM1-positive patients
from our case series tend to have a higher p53 mutation frequency
than GSTM1-deficient individuals (Table 4). Taken together, our
data indicate that the influence of GSTM1 on p53 mutagenesis is
small in the Silesian cases.
The role of CYP2D6 in modulating lung cancer susceptibility is
controversial. So far, two tobacco smoke components: 4-(methyl-
nitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and nicotine, have
been proposed as substrates for CYP2D6 (Crespi et al, 1991;
Cholerton et al, 1994). The frequency of predicted phenotypes for
our group of patients is almost identical to the frequency of pheno-
types determined by pharmacogenetic methods in a healthy Polish
population (EM: 58% by genotyping vs 57% by metabolite
measurements, IM 37% vs 37%, PM 5% vs 6%) (Kunicki et al,
1995). Considering the CYP2D6 genotype (presence of alleles Aand
B), we classified the patients by the two predicted phenotypes (EM
or IM and PM). Since we detected only nine patients with predicted
PM phenotype, it was not possible to reasonably compare muta-
tional spectra between CYP2D6 proficient and deficient individuals.
Our study demonstrated that the use of the anti-p21WAF1/CIP1 anti-
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lung tissue unstained. In our material, the p21WAF1/CIP1 product
occurred independently of the status of p53 protein or gene. Study
performed on a different NSCLC case series from the USA yielded
similar results (Bennett et al, 1998). In conclusion, we observed
that more than 50% of NSCLC patients had mutations within p53 in
DNA isolated from tumour tissues. In contrast with other studies
(reviewed in Greenblatt et al, 1994; Hainaut et al, 1998; Hussain
and Harris, 1998), the never smokers had a high frequency of
G:CÕT:A transversions. We observed that males exposed occupa-
tionally to coal dust and coal processing substances (mostly coal
miners) constitute a group of patients that can be characterized by a
relatively high frequency of squamous and large-cell carcinomas,
relatively frequent nonsense mutations in codon 298 of p53, and a
relatively low frequency of p53 immunohistochemistry-positive
tumours. These data are a tentative indication that occupational and
environmental exposure to polluted air contributes to the molecular
pathogenesis of lung cancer in Silesian residents.
ACKNOWLEDGEMENTS
This work was supported in part by grants from the State Com-
mittee for Scientific Research (KBN) # 6P20706405p03,
# 6P20706405p02 for the Department of Tumour Biology and
profited also from Polish-American MSC Fund II grant
# MZ/HHS-93-133. MC thanks the Fogarty International Center,
NIH, MD, USA for fellowship, 5F05. TW04836-03. We would like
to thank Ms A Kyrcz, Ms I Matuszczyk, Ms H Paterak, Ms I Peick,
Ms H Waniek and Mr A Samojedny for their excellent technical
assistance.
The editorial assistance of Ms Dorothea Dudek is also appreciated.
REFERENCES
Alexandrie AK, Ingelman Sundberg M, Seidegard J, Tornling G and Rannung A
(1994) Genetic susceptibility to lung cancer with special emphasis on CYP1A1
and GSTM1: a study on host factors in relation to age at onset, gender and
histological cancer types. Carcinogenesis 15: 1785–1790
Ayesh R, Idle JR, Ritchie JC, Crothers MJ and Hetzel MR (1984) Metabolic
oxidation phenotypes as markers for susceptibility to lung cancer. Nature 312:
169–170
Bennett WP, Colby TV, Travis WD, Borkowski A, Jones RT, Lane DP, Metcalf RA,
Samet JM, Takeshima Y, Gu JR, Vahakangas KH, Soini Y, Paakko P, Welsh JA,
Trump BF and Harris CC (1993) p53 protein accumulates frequently in early
bronchial neoplasia. Cancer Res 53: 4817–4822
Bennett WP, El-Deiry WS, Guinee DG, Freedman AN, Rush WL, Caporaso NE,
Welsh JA, Jones RT, Borkowski A, Travis WD, Fleming MV, Trastek V,
Pairolero PC, Tazelaar HD, Midthun D, Jett JR, Liotta LA and Harris CC
(1998) p21waf1/cip1 and transforming growth factor b1 protein expression
correlate with survival in non-small cell lung cancer. Clin Cancer Res 4:
1499–1506
Caporaso N, Hayes RB, Dosemeci M, Hoover R, Ayesh R, Hetzel M and Idle J
(1989) Lung cancer risk, occupational exposure, and the debrisoquine
metabolic phenotype. Cancer Res 49: 3675–3679
Caporaso N, DeBaun MR and Rothman N (1995) Lung cancer and CYP2D6 (the
debrisoquine polymorphism): sources of heterogeneity in the proposed
association. Pharmacogenetics 5: 129–134
Cariello NF, Piegorsch WW, Adams WT and Skopek TR (1994) Computer program
for the analysis of mutational spectra: application to p53 mutations.
Carcinogenesis 15: 2281–2285
Cholerton S, Arpanahi A, McCracken N, Boustead C, Taber H, Johnstone E,
Leathart J, Daly AK and Idle JR (1994) Poor metabolisers of nicotine and
CYP2D6 polymorphism. Lancet 343: 62–63
Chorazy M, Szeliga J, Strozyk M and Cimander B (1994) Ambient air pollutants in
Upper Silesia: partial chemical composition and biological activity. Environ
Health Perspect 102: 61–66
Crespi CL, Penman BW, Gelboin HV and Gonzales FJ (1991) A tobacco smoke-
derived nitrosoamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, is
activated by multiple human cytochrome P450s including the polymorphic
human cytochrome P4502D6. Carcinogenesis 12: 1197–1201
Denissenko MF, Pao A, Pfeifer GP and Tang M (1998) Slow repair of bulky DNA
adducts along the nontranscribed strand of the human p53 gene may explain
the strand bias of transversion mutations in cancers. Oncogene 16:
1241–1247
El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D,
Mercer WE, Kinzler KW and Vogelstein B (1993) WAF1, a potential mediator
of p53 tumor suppression. Cell 75: 817–825
Evans MK, Taffe BG, Harris CC and Bohr VA (1993) DNA strand bias in the repair
of the p53 gene in normal human and xeroderma pigmentosum group C
fibroblasts. Cancer Res 53: 5377–5381
Greenblatt MS, Bennett WP, Hollstein M and Harris CC (1994) Mutations in the p53
tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.
Cancer Res 54: 4855–4878
Grzybowska E, Hemminki K and Chorazy M (1993) Seasonal variation in level of
DNA adducts and X-spots in human populations living in different parts of
Poland. Environ Health Perspect 99: 77–81
Gualberto A, Aldape K, Kozakiewicz K and Tlsty TD (1998) An oncogenic form of
p53 confers a dominant, gain-of-function phenotype that disrupts spindle
checkpoint control. Proc Natl Acad Sci USA 95: 5166–5171
Haupt Y, Maya R, Kazaz A and Oren M (1997) Mdm2 promotes the rapid
degradation of p53. Nature 387: 296–299
Hainaut P, Hernandez T, Robinson A, Rodriguez-Tome P, Flores T, Hollstein M,
Harris CC and Montesano R (1998) IARC Database of p53 gene mutations in
human tumors and cell lines: updated compilation, revised formats and new
visualisation tools. Nucleic Acids Res 26: 205–213
Harper JW, Adami GR, Wei N, Keyomarsi K and Elledge SJ (1993) The p21 Cdk-
interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Cell 75: 805–816
Harris CC (1993) p53 at the crossroads of molecular carcinogenesis and risk
assesment. Science 262: 1980–1981
Harris CC (1996) p53 tumor suppressor gene: from the basic research laboratory to
the clinic – an abridged historical perspective. Carcinogenesis 17: 1187–1198
Hayashi S, Watanabe J and Kawajiri K (1992) High susceptibility to lung cancer
analyzed in terms of combined genotypes of P450IA1 and Mu-class glutathione
S-transferase genes. Jpn J Cancer Res 83: 866–870
Heim M and Meyer UA (1990) Genotyping of poor metabolisers of debrisoquine by
allele-specific PCR amplification. Lancet 336: 529–532
Hirvonen A, Husgafvel-Pursiainen K, Anttila S and Vainio H (1993) The GSTM1
null genotype as a potential risk modifier for squamous cell carcinoma of the
lung. Carcinogenesis 14: 1479–1481
Hollstein M, Sidransky D, Vogelstein B and Harris CC (1991) p53 mutations in
human cancers. Science 253: 49–53
Hussain SP and Harris CC (1998) Molecular epidemiology of human cancer:
contribution of mutation spectra studies of tumor suppressor genes. Cancer Res
58: 4023–4037
IARC Monographs on the Evaluation of Carcinogenic Risks to Humans (1986)
Volume 38, Tobacco Smoking. IARC: Lyon
Iggo R, Gatter K, Bartek J, Lane D and Harris AL (1990) Increased expression
of mutant forms of p53 oncogene in primary lung cancer. Lancet 335:
675–679
Kato S, Bowman ED, Harrington AM, Blomeke B and Shields PG (1995) Human
lung carcinogen–DNA adduct levels mediated by genetic polymorphisms in
vivo. J Natl Cancer Inst 87: 902–907
Kawajiri K, Eguchi H, Nakachi K, Sekiya T and Yamamoto M (1996) Association of
CYP1A1 germ line polymorphisms with mutations of the p53 gene in lung
cancer. Cancer Res 56: 72–76
Kihara M, Kihara M and Noda K (1994) Lung cancer risk of GSTM1 null genotype
is dependent on the extent of tobacco smoke exposure. Carcinogenesis 15:
415–418
Ko LJ and Prives C (1996) p53: puzzle and paradigm. Genes Dev 10: 1054–1072
Kondo K, Tsuzuki H, Sasa M, Sumitomo M, Uyama T and Monden Y (1996) A
dose–response relationship between the frequency of p53 mutations and
tobacco consumption in lung cancer patients. J Surg Oncol 61: 20–26
Kubbutat MH, Jones SN and Vousden KH (1997) Regulation of p53 stability by
Mdm2. Nature 387: 299–303
Kuempel ED, Stayner LT, Attfield MD and Buncher CR (1995) Exposure–response
analysis of mortality among coal miners in the United States. Am J Ind Med 28:
167–184
Kunicki PK, Sitkiewicz D, Pawlik A, Bielicka-Sulzyc V, Borowiecka E, Gawronska-
Szklarz B, Sterna R, Matsumoto H and Radziwon-Zaleska M (1995)
Debrisoquine hydroxylation in a Polish population. Eur J Clin Pharmacol 47:
p53 mutations and air pollution 1451
British Journal of Cancer (1999) 80(9), 1445–1452 © 1999 Cancer Research Campaign 503–505
Legros Y, Lacabanne V, d’Agay MF, Larsen CJ, Pla M and Soussi T (1993)
Production of human p53 specific monoclonal antibodies and their use in
immunohistochemical studies of tumor cells. Bull Cancer 80: 102–110
Lehman TA, Bennett WP, Metcalf RA, Welsh JA, Ecker J, Modali RV, Ullrich S,
Romano JW, Appella E, Testa JR, Gerwin BI and Harris CC (1991) p53
mutations, ras mutations and p53-heat shock protein complexes in human lung
cell lines. Cancer Res 51: 4090–4096
Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88:
323–331
Meijers JM, Swaen GM, Slangen JJ, van Vliet K and Sturmans F (1991) Long-term
mortality in miners with coal workers’ pneumoconiosis in The Netherlands: a
pilot study. Am J Ind Med 19: 43–50
Miller AB (1992) Epidemiology, prevention, prognostic factors and natural history
of lung cancer. Current Opinion Oncol 4: 286–291
Miller BG and Jacobsen M (1985) Dust exposure, pneumoconiosis, and mortality of
coalminers. Br J Ind Med 42: 723–733
Motykiewicz G, Michalska J, Pendzich J, Perera FP and Chorazy M (1992) A
cytogenetic study of men environmentally and occupationally exposed to
airborne pollutants. Mutat Res 280: 253–259
Motykiewicz G, Malusecka E, Grzybowska E, Chorazy M, Zhang YJ, Perera FP and
Santella RM (1995) Immunohistochemical quantitation of polycyclic aromatic
hydrocarbon–DNA adducts in human lymphocytes. Cancer Res 55: 1417–1422
Nakachi K, Imai K, Hayashi S and Kawajiri K (1993) Polymorphisms of the
CYP1A1 and glutathione S-transferase genes associated with susceptibility to
lung cancer in relation to cigarette smoking dose in a Japanese population.
Cancer Res 53: 2994–2999
Perera FP, Hemminki K, Gryzbowska E, Motykiewicz G, Michalska J, Santella RM,
Young TL, Dickey C, Brandt-Rauf P, DeVivo I, Blaner W, Tsai WY and
Chorazy M (1992) Molecular and genetic damage in humans from
environmental pollution in Poland. Nature 360: 256–258
Petersen G (1994) Epidemiology, screening, and prevention of lung cancer. Curr
Opin Oncol 6: 156–161
Przygodzki RM, Bennett WP, Guinee MD, Khan MA, Freedman A, Shields PG,
Travis WD, Jett JR, Tazelaar H, Pairolero P, Trastek V, Liotta LA, Harris CC
and Caporaso NE (1998) p53 mutation spectrum in relation to GSTM1,
CYP1A1 and CYP2E1 in surgically treated patients with non-small cell lung
cancer. Pharmacogenetics (in press)
Rebbeck TR (1997) Molecular epidemiology of the human glutathione S-transferase
genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol
Biomarkers Prev 6: 733–743
Ruggeri B, DiRado M, Zhang SY, Bauer B, Goodrow T and Klein-Szanto AJ (1993)
Benzo[a]pyrene-induced murine skin tumors exhibit frequent and characteristic
G to T mutations in the p53 gene. Proc Natl Acad Sci USA 90: 1013–1017
Ryberg D, Kure E, Lystad S, Skaug V, Stangelend L, Mercy I, Borresen A-L and
Haugen A (1994) p53 mutations in lung tumors: relation to putative
susceptibility markers for cancer. Cancer Res 54: 1551–1555
Sambrook J, Fritsch EF and Maniatis T (1989) Molecular Cloning: a Laboratory
Manual, 2nd edn. Cold Spring Harbor Laboratory Press: Cold Spring Harbor,
NY
Shields PG, Bowman ED, Harrington AM, Doan VT and Weston A (1993)
Polycyclic aromatic hydrocarbon–DNA adducts in human lung and cancer
susceptibility genes. Cancer Res 53: 3486–3492
Speizer FE and Samet JM (1994) Air pollution and lung cancer. In: Epidemiology of
Lung Cancer, Samet JM (ed), pp. 131–150. Marcel Dekker: New York
Sozzi G, Miozzo M, Donghi R, Pilotti S, Cariani CT, Pastorino U, Della Porta G and
Pierotti MA (1992) Deletions of 17p and p53 mutations in preneoplastic lesions
of the lung. Cancer Res 52: 6079–6082
Starzynski Z, Marek K, Kujawska A and Szymczak W (1996) Mortality among
different occupational groups of workers with pneumoconiosis: results from a
register-based cohort study. Am J Ind Med 30: 718–725
Stucker I, Cosme J, Laurent Ph, Cenee S, Beaune Ph, Bignon J, Depierre A,
Milleron B and Hemon D (1995) CYP2D6 genotype and lung cancer risk
according to histologic type and tobacco exposure. Carcinogenesis 16:
2759–2764
Sugimura H, Caporaso NE, Shaw GL, Modali RV, Gonzalez FJ, Hoover RN, Resau
JH, Trump BF, Weston A and Harris CC (1990) Human debrisoquine
hydroxylase gene polymorphisms in cancer patients and controls.
Carcinogenesis 11: 1527–1530
Takeshima Y, Seyama T, Bennett WP, Akiyama M, Tokuoka S, Inai K, Mabuchi K,
Land CE and Harris CC (1993) p53 mutations in lung cancers from non-
smoking atomic-bomb survivors. Lancet 342: 1520–1521
Tefre T, Daly AK, Armstrong M, Leathart JBS, Idle JR, Brogger A and Borresen
A-L (1994) Genotyping of the CYP2D6 gene in Norwegian lung cancer
patients and controls. Pharmacogenetics 4: 47–57
Wang X, Christioni DC, Wincke JK, Fischbein M, Cheng TJ, Mark E, Wain JC and
Kelsey KT (1995) Mutations in the p53 gene in lung cancer are associated with
cigarette smoking and asbestos exposure. Cancer Epidemiol Biomarkers Prev
4: 543–548
Vahakangas KH, Samet JM, Metcalf RA, Welsh JA, Bennett WP, Lane DP and
Harris CC (1992) Mutations of p53 and ras genes in radon-associated lung
cancer from uranium miners. Lancet 339: 576–580
Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R and Beach D (1993) p21 is a
universal inhibitor of cyclin kinases. Nature 366: 701–704
1452 M Rusin et al
British Journal of Cancer (1999) 80(9), 1445–1452 © 1999 Cancer Research Campaign 